SPOTLIGHT -
ASRS 2019 Street Team: Peter K. Kaiser, MD
Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD.
Read More
ASRS 2019 Street Team: Kevin Blinder, MD
ICYMI: Dr. Blinder compares the efficiencies between two surgical cutters
ASRS 2019 Street Team: Nancy M. Holekamp, MD
Eyes with persistent subretinal fluid fared better with visual acuity than eyes that were dry, according to the HARBOR Trial
Lack of transportation jeopardizes free primary eye care
Short drive times, access to transportation play role in maintaining eye health appointments
Hospital utilization and its effects on vision
Here's how hospital stays can affect vision
7 pediatric eye myths parents should stop believing
Regeneron gets FDA approval for Eylea injection prefilled syringe
Online symptom checkers: Do they work?
JAMA Ophthalmology investigates the accuracy claims of this convenient modality
Top ophthalmic challenges in 2019
Ophthalmology Times’ Editorial Advisory Board members share their thoughts on what to watch in year ahead